Alzheimer's Disease Clinical Trials in New York

Showing 181-200 of 291 trials

Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05

NCT02795780

This study will evaluate longitudinal change of tau deposition as measured by flortaucipir F 18 uptake over time.

Avid Radiopharmaceuticals79 participantsStarted Aug 2016

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Scottsdale, Arizona, United States +19 more locations

TERMINATEDPhase 3< 1 mile

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

NCT03114657

This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (Q4W) for 100 weeks. The primary efficacy assessment will be performed at 105 weeks. The participants who do not enter open-label extension will enter for a long term follow-up period for up to 52 weeks after the last crenezumab dose (Week 153).

Alzheimer's Disease

Hoffmann-La Roche806 participantsStarted Mar 2017

Scottsdale, Arizona, United States • Fayetteville, Arkansas, United States • Little Rock, Arkansas, United States +208 more locations

Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

Alzheimer's Disease Trials in Other Cities

Brain Sleep Deprivation MRI Effects (BEDTIME)

Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly

A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab

Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo

Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

Northern Manhattan Caregiver Intervention Project

Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease

Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease

A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease

Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)

A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease

Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

Other Conditions in New York